188 related articles for article (PubMed ID: 35632748)
1. HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models.
Rodríguez MDCR; Rodríguez IG; Nattress C; Qureshi A; Halldén G
Viruses; 2022 May; 14(5):. PubMed ID: 35632748
[TBL] [Abstract][Full Text] [Related]
2. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.
Man YKS; Davies JA; Coughlan L; Pantelidou C; Blázquez-Moreno A; Marshall JF; Parker AL; Halldén G
Mol Cancer Ther; 2018 Feb; 17(2):575-587. PubMed ID: 29367266
[TBL] [Abstract][Full Text] [Related]
3. Complexing the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models.
Man YKS; Aguirre-Hernandez C; Fernandez A; Martin-Duque P; González-Pastor R; Halldén G
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012152
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models.
Miao T; Symonds A; Hickman OJ; Wu D; Wang P; Lemoine N; Wang Y; Linardopoulos S; Halldén G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279262
[TBL] [Abstract][Full Text] [Related]
5. Advances in oncolytic adenovirus therapy for pancreatic cancer.
Nattress CB; Halldén G
Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
[TBL] [Abstract][Full Text] [Related]
6. GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment.
Chang HG; Choi YH; Hong J; Choi JW; Yoon AR; Yun CO
Cells; 2021 Oct; 10(11):. PubMed ID: 34831034
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
[TBL] [Abstract][Full Text] [Related]
8. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
9. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
[TBL] [Abstract][Full Text] [Related]
10. Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses.
Green-Tripp G; Nattress C; Halldén G
Front Mol Biosci; 2022; 9():901392. PubMed ID: 35813830
[TBL] [Abstract][Full Text] [Related]
11. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
13. Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.
Kaczorowski A; Hammer K; Liu L; Villhauer S; Nwaeburu C; Fan P; Zhao Z; Gladkich J; Groß W; Nettelbeck DM; Herr I
Oncotarget; 2016 Feb; 7(8):9046-59. PubMed ID: 26824985
[TBL] [Abstract][Full Text] [Related]
14. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Zhang K; Liu Z; Yao Y; Qiu Y; Li F; Chen D; Hamilton DJ; Li Z; Jiang S
J Med Chem; 2021 Apr; 64(7):4020-4033. PubMed ID: 33745280
[TBL] [Abstract][Full Text] [Related]
18. miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity.
Bofill-De Ros X; Gironella M; Fillat C
Mol Ther; 2014 Sep; 22(9):1665-77. PubMed ID: 24895996
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
20. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
Oberg D; Yanover E; Adam V; Sweeney K; Costas C; Lemoine NR; Halldén G
Clin Cancer Res; 2010 Jan; 16(2):541-53. PubMed ID: 20068104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]